Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Peter Lin MD, CCFP
Peter Lin MD, CCFP Associate Editor
David Rakel MD, FAAFP
David Rakel MD, FAAFP Editor-in-Chief
Dipesh Navsaria MPH, MSLIS, MD
Dipesh Navsaria MPH, MSLIS, MD Advisory Board
See All Experts
featured
Published in Primary Care and
1 other channel

Journal Scan / Research · July 08, 2019

P2Y12 Inhibitor Monotherapy Is Noninferior to Dual Antiplatelet Therapy After PCI

JAMA: The Journal of the American Medical Association

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Deepak Bhatt MD, MPH, FACC, FAHA, FESC, MSCAI

Peter Lin MD, CCFP

JAMA: The Journal of the American Medical Association
Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial
JAMA 2019 Jun 25;321(24)2428-2437, JY Hahn, YB Song, JH Oh, WJ Chun, YH Park, WJ Jang, ES Im, JO Jeong, BR Cho, SK Oh, KH Yun, DK Cho, JY Lee, YY Koh, JW Bae, JW Choi, WS Lee, HJ Yoon, SU Lee, JH Cho, WG Choi, SW Rha, JM Lee, TK Park, JH Yang, JH Choi, SH Choi, SH Lee, HC Gwon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Recently Updated